<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Wilson disease: Clinical manifestations, diagnosis, and natural history
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Wilson disease: Clinical manifestations, diagnosis, and natural history
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Wilson disease: Clinical manifestations, diagnosis, and natural history
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael L Schilsky, MD, FAASLD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth B Rand, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bruce A Runyon, MD, FAASLD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael J Aminoff, MD, DSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen M Robson, MD, MBA, FACG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 31, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H69501357">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Wilson disease (also referred to as hepatolenticular degeneration) is a genetic disorder of copper metabolism with an autosomal recessive pattern of inheritance that leads to impaired function of the intracellular copper transporter ATP7B. Reduced biliary excretion of copper results in its accumulation in the liver and other tissues (eg, brain, cornea). Most patients have liver involvement that may range from asymptomatic elevations in liver biochemistries (eg, serum aminotransferases, bilirubin) to cirrhosis or acute liver failure. Some patients develop symptoms related to neurologic involvement.
        </p>
        <p>
         This topic will discuss the clinical manifestations, diagnosis, and natural history of Wilson disease. Other aspects of Wilson disease are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Epidemiology and pathogenesis – (See
         <a class="medical medical_review" href="/z/d/html/3626.html" rel="external">
          "Wilson disease: Epidemiology and pathogenesis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Interpretation of genetic testing for
         <em>
          ATP7B
         </em>
         (Wilson disease gene) – (See
         <a class="medical medical_review" href="/z/d/html/131793.html" rel="external">
          "Gene test interpretation:
          <i>
           ATP7B
          </i>
          (Wilson disease gene)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management – (See
         <a class="medical medical_review" href="/z/d/html/3591.html" rel="external">
          "Wilson disease: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H69500435">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H3088023393">
         <span class="h2">
          Patterns of clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Wilson disease has a variety of clinical phenotypes; thus, it may be included in the differential diagnosis for patients with abnormal liver biochemical tests, chronic hepatitis, cirrhosis, or acute liver failure [
         <a href="#rid1">
          1,2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">
          "Approach to the patient with abnormal liver biochemical and function tests"
         </a>
         .)
        </p>
        <p>
         The spectrum of presentation also includes patients with isolated neuropsychiatric symptoms and asymptomatic patients. Some patients have a combination of hepatic and extrahepatic symptoms. A non-immune (Coombs-negative) hemolysis is common in patients with acute liver failure due to Wilson disease, but it may also occur in the absence of acute liver failure.
        </p>
        <p>
         The reported rates of organ-specific manifestations at the time of presentation vary widely [
         <a href="#rid1">
          1,3-8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liver disease: 18 to 84 percent of patients
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neurologic symptoms: 18 to 73 percent of patients
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychiatric symptoms: 10 to 100 percent of patients
        </p>
        <p>
        </p>
        <p>
         The wide variability in these estimates may be attributable to lead-time bias with respect to the age at which a patient is seen, as well as ascertainment bias based on the clinical specialty to which the patient was referred (eg, neurologists are more likely to see patients with neurologic symptoms, whereas pediatricians are less likely). (See
         <a class="local">
          'Age at symptom onset'
         </a>
         below.)
        </p>
        <p>
         Regardless of whether clinical manifestations are initially present, patients often develop manifestations of organ-specific involvement as the disease progresses (eg, patients who present with liver disease may subsequently develop neurologic or psychiatric symptoms). Conversely, liver failure may develop in patients who presented initially with neurologic or psychiatric symptoms.
        </p>
        <p class="headingAnchor" id="H57950462">
         <span class="h2">
          Age at symptom onset
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with Wilson disease develop symptoms between the ages of 3 and 55 years, although the disorder has been diagnosed in patients under the age of three years and in patients in their eighth decade [
         <a href="#rid9">
          9-11
         </a>
         ]. In a study of 143 pediatric patients with Wilson disease, 21 patients (15 percent) presented with symptoms or abnormal liver biochemistries before the age of five years [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Most symptomatic pediatric patients (ie, &lt;18 years of age) present with liver disease alone, whereas symptomatic adults have liver disease with or without neurologic symptoms. However, individuals who are diagnosed through family screening because of an affected first-degree relative are often asymptomatic, regardless of age.
        </p>
        <p>
         The mechanisms for copper excretion are not well developed in newborns and begin to function more efficiently within the first year of life. For patients with Wilson disease, a critical
         <em>
          ATP7B
         </em>
         -dependent copper excretory pathway fails to develop or is dysfunctional, and copper accumulation that begins at birth continues throughout life, gradually producing clinical disease [
         <a href="#rid12">
          12
         </a>
         ]. In most patients, liver disease progresses silently, often until adolescence and beyond, when acute liver failure or complications of cirrhosis may develop. In some patients, neurologic or psychiatric manifestations precede overt liver disease.
        </p>
        <p>
         The variability in the age of onset of Wilson disease probably reflects differences in mutations and penetrance, extragenic factors, and environmental influences including diet [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3626.html" rel="external">
          "Wilson disease: Epidemiology and pathogenesis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H702206632">
         <span class="h2">
          Manifestations of copper accumulation
         </span>
        </p>
        <p class="headingAnchor" id="H69500442">
         <span class="h3">
          Liver disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The liver is a major site of copper accumulation in Wilson disease. Clinical presentation of liver involvement ranges from asymptomatic elevations in liver biochemistries (often with steatosis) to acute liver injury/failure (often with an associated non-immune hemolytic anemia) or to chronic hepatitis and cirrhosis. Regardless of presenting symptoms, some degree of liver disease, even if only histologic change, is usually present at the time of diagnosis [
         <a href="#rid14">
          14
         </a>
         ]. Approximately 5 to 25 percent of patients with liver involvement do not report any symptoms.
        </p>
        <p>
         The clinical features vary with the degree of liver damage [
         <a href="#rid1">
          1,15
         </a>
         ]. Patients with copper accumulation in the liver may present with (see
         <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">
          "Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Clinical manifestations'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abdominal pain (acute hepatitis, acute liver failure)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Jaundice (acute hepatitis, acute liver failure with hemolytic anemia, cirrhosis)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatomegaly (acute and chronic hepatitis, acute liver failure)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Splenomegaly (cirrhosis with portal hypertension)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ascites (cirrhosis with portal hypertension)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Upper gastrointestinal bleeding from varices or portal hypertensive gastropathy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral stigmata of chronic liver disease (cirrhosis)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mental status changes due to hepatic encephalopathy (acute liver failure, cirrhosis)
        </p>
        <p>
        </p>
        <p>
         Laboratory test findings may include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low level of serum ceruloplasmin (may be seen with all forms of liver involvement, although not as consistently with acute liver failure)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated aminotransferases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST])
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low alkaline phosphatase
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thrombocytopenia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coagulopathy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Non-immune hemolytic anemia
        </p>
        <p>
        </p>
        <p>
         Abdominal imaging may show:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liver steatosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatomegaly
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A small, nodular liver
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Splenomegaly
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ascites
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Varices and/or patent umbilical vein
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Portosystemic shunt (ie, splenorenal)
        </p>
        <p>
        </p>
        <p>
         Liver histologic findings may include fatty infiltration within hepatocytes, glycogen inclusions within nuclei, and portal fibrosis, especially earlier in the course of the disease  (
         <a class="graphic graphic_picture graphicRef64346" href="/z/d/graphic/64346.html" rel="external">
          picture 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H69501971">
         <span class="h4">
          Acute liver injury/failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute liver injury in patients with Wilson disease manifests initially as abdominal pain and jaundice that progresses to liver failure. Most patients have underlying advanced fibrosis or cirrhosis; thus, the condition may be referred to as acute on chronic liver failure (ACLF) [
         <a href="#rid16">
          16
         </a>
         ]. In contrast, acute liver failure refers to the rapid (typically in less than 8 to 12 weeks) development of severe acute liver injury with impaired synthetic function with coagulopathy and encephalopathy in an individual who previously had a normal liver. (See
         <a class="medical medical_review" href="/z/d/html/16142.html" rel="external">
          "Acute liver failure in children: Etiology and evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3574.html" rel="external">
          "Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
         Features of ACLF related to Wilson disease include [
         <a href="#rid17">
          17,18
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Non-immune (Coombs-negative) hemolytic anemia results from the effects of excess copper ions on the red blood cell membrane in the circulation due to hepatic copper release following cellular necrosis [
         <a href="#rid19">
          19,20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7168.html" rel="external">
          "Non-immune (Coombs-negative) hemolytic anemias in adults"
         </a>
         .).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coagulopathy unresponsive to parenteral administration of Vitamin K.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated aminotransferases (typically &lt;2000 international units/L). The ratio of the AST to ALT is often &gt;2.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normal or markedly low serum alkaline phosphatase (typically &lt;40 international units/L). The ratio of the alkaline phosphatase (international unit/L) to total bilirubin (mg/dL) is typically &lt;4.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapidly progressive kidney failure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low uric acid levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Female to male ratio of 2:1 to 4:1 [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Ceruloplasmin levels are less reliable for diagnosing ACLF due to Wilson disease because ceruloplasmin is an acute phase reactant, which may elevate levels [
         <a href="#rid16">
          16
         </a>
         ]. Alternatively, ceruloplasmin levels can be depressed due to severe liver synthetic dysfunction.
        </p>
        <p class="headingAnchor" id="H69501979">
         <span class="h4">
          Chronic liver disease and cirrhosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with chronic hepatitis due to Wilson disease are often asymptomatic from their liver disease. It has been estimated that 35 to 45 percent of patients have cirrhosis at the time of diagnosis of Wilson disease [
         <a href="#rid22">
          22-24
         </a>
         ]. Such patients are typically diagnosed through family screening, after presenting with neurologic or psychiatric manifestations, or during an evaluation for abnormal liver biochemical tests or imaging. Serum aminotransferases are usually mildly to moderately elevated (ie, &lt;5 times the upper limit of normal) in asymptomatic patients with Wilson disease. AST is usually higher than ALT. Wilson disease often results in liver steatosis and may be diagnosed in a patient being evaluated for steatotic liver disease [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Most patients with chronic liver disease have low serum ceruloplasmin, but only 50 percent have Kayser-Fleischer (KF) rings. On liver biopsy, nearly all patients have a hepatic copper concentration &gt;250 mcg/g dry weight liver, but few patients have levels as low as 75 mcg/g dry weight liver, with normal being &lt;40 mcg/g dry weight liver [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         As the disease progresses, patients may develop cirrhosis with or without complications such as ascites or variceal bleeding. (See
         <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">
          "Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         Of note, the magnitude of aminotransferase elevation correlates poorly with the extent of histologic injury [
         <a href="#rid25">
          25,26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H69501597">
         <span class="h3">
          Neurologic involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neurologic manifestations of Wilson disease vary widely. Nearly all patients with Wilson disease with neurologic manifestations have KF rings. Neurologic symptoms may be subtle or may be rapidly progressive, leading to severe disability over the course of months [
         <a href="#rid27">
          27
         </a>
         ]. In patients with known cirrhosis, neurologic manifestations may be mistaken for hepatic encephalopathy.
        </p>
        <p>
         Most patients with neurologic involvement have at least one of the following features [
         <a href="#rid1">
          1,28-30
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dysarthria
         </strong>
         – Dysarthria is common and has been reported in up to 97 percent of patients with neurologic manifestations. The type of dysarthria varies and includes ataxic dysarthria (irregular word spacing and volume) and athetoid, hypophonic, or spastic speech.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cerebellar ataxia/abnormal gait
         </strong>
         – Cerebellar ataxia is generally not seen as the sole neurologic manifestation of Wilson disease, but it has been reported in 30 to 75 percent of patients with Wilson disease [
         <a href="#rid1">
          1
         </a>
         ]. The ataxia is typically not clinically relevant, and frank limb ataxia is uncommon.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with cerebellar ataxia have difficulty changing voluntary force levels abruptly, with impaired acceleration and braking [
         <a href="#rid31">
          31
         </a>
         ]. This may lead to overshoot in point-to-point movements (dysmetria); breakdown of normal coordination of joint rotations, with trajectory abnormalities (dyssynergia in multi-joint movements); and breakdown in the rhythm of repetitive, alternating single movements, such as finger tapping (dysrhythmia) [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Dysfunction in the vermis or paleocerebellum results in truncal and gait ataxia. (See
         <a class="medical medical_review" href="/z/d/html/4910.html" rel="external">
          "Approach to abnormal gait in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dystonia
         </strong>
         – Reported rates of dystonia in patients with Wilson disease have ranged from 38 to 69 percent. Dystonia may range in severity from mild to debilitating, and it often worsens with disease progression [
         <a href="#rid1">
          1
         </a>
         ]. Dystonia may be focal, segmental, multifocal, or generalized. While it can occur unilaterally, it may eventually become bilateral or generalized. In some patients with severe dystonia, contractures may develop and may only be corrected with surgical tendon lengthening. (See
         <a class="medical medical_review" href="/z/d/html/4886.html" rel="external">
          "Etiology, clinical features, and diagnostic evaluation of dystonia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Focal manifestations of dystonia include blepharospasm, cervical dystonia (torticollis), writer's cramp, and a dystonic facial expression in which the patient appears to have an exaggerated smile (risus sardonicus). In addition, focal dystonia may involve the vocal cords (dysphonia), muscles of articulation (dysarthria), or swallowing muscles (dysphagia).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tremor
         </strong>
         – Tremors in Wilson disease have been reported in up to 55 percent of patients. Tremors may occur at rest or with action and may have multiple position and task-dependent characteristics [
         <a href="#rid1">
          1
         </a>
         ]. Specific types of tremor include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Postural tremor that occurs when the patient assumes a particular position. The classic tremor associated with Wilson disease is a wing-beating tremor, although it is not the most common type of tremor [
         <a href="#rid1">
          1
         </a>
         ]. The tremor is a low-frequency, high-amplitude tremor that is most prominent when the patient's arms are held outstretched laterally or with the arms extended in front of the patient with the palms facing downward and the elbows flexed. The tremor increases in amplitude with increased duration of posture holding. The name comes from the fact that the movement of the patient's arms may resemble a bird's flapping wings.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A tremor that resembles essential tremor (variable amplitude and frequency, with arm and sometimes head and leg involvement). However, unlike essential tremor, the tremor in Wilson disease often persists in its asymmetry and may not involve the voice. (See
         <a class="medical medical_review" href="/z/d/html/4895.html" rel="external">
          "Overview of tremor", section on 'Essential tremor'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intention (kinetic) tremor (low amplitude, medium-to-high frequency). These intention tremors are seen most often in a distal upper extremity and typically increase in severity as the patient's hand moves closer to its target. (See
         <a class="medical medical_review" href="/z/d/html/4895.html" rel="external">
          "Overview of tremor", section on 'Cerebellar tremor'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Unilateral rest tremor. A unilateral rest tremor may be present and is typically accompanied by postural and intention tremors [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Parkinsonism
         </strong>
         – Parkinsonian movement disorder has been reported in 12 to 58 percent of patients. Specific features include bradykinesia, cogwheel rigidity, and postural instability. Parkinsonism is rarely an isolated clinical feature and is typically accompanied by other neurologic deficits. [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Less common neurologic manifestations include [
         <a href="#rid28">
          28-30
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chorea/athetosis
         </strong>
         – Chorea is characterized by rapid and unpredictable contractions affecting mostly distal limbs, but it can also affect the face and trunk. The movements are involuntary and non-patterned with variable speed, timing, and direction, flowing from one body part to another. In less severe cases, this can result in an appearance of fidgeting. The unpredictable nature of chorea is a feature that distinguishes it from tremor and dystonia [
         <a href="#rid33">
          33
         </a>
         ]. When it is severe and involves proximal muscle(s), choreic movements may result in violent, uncontrolled flailing movements of the extremities (ballism). Athetosis refers to slower writhing movements with a sinuous quality. The term choreoathetosis is used when typical choreic movements coexist with athetosis. (See
         <a class="medical medical_review" href="/z/d/html/14133.html" rel="external">
          "Overview of chorea"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Chorea is seen more often in younger patients (≤16 years of age) and typically occurs in combination with other neurologic symptoms [
         <a href="#rid1">
          1,34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cognitive impairment
         </strong>
         – Cognitive impairment in Wilson disease may be manifested as a frontal syndrome or subcortical dementia, with some patients having features of both [
         <a href="#rid1">
          1
         </a>
         ]. In patients with cognitive impairment, the findings can be subtle and may only be recognized retrospectively. For patients with new onset cognitive changes, it is important to exclude hepatic encephalopathy. (See
         <a class="medical medical_review" href="/z/d/html/1237.html" rel="external">
          "Hepatic encephalopathy in adults: Clinical manifestations and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with a frontal syndrome may demonstrate impulsivity, promiscuity, impaired judgement, apathy, executive dysfunction (eg, poor planning and decision-making), decreased attention, and emotional lability. When severe, patients may have pseudobulbar features (sudden outbursts of inappropriate laughter or tearfulness). (See
         <a class="medical medical_review" href="/z/d/html/5070.html" rel="external">
          "Frontotemporal dementia: Clinical features and diagnosis", section on 'Behavioral variant FTD'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Findings in subcortical dementia include slowed thinking, memory loss, and executive dysfunction. However, patients with subcortical dementia lack cortical signs such as aphasia, apraxia, or agnosia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seizures
         </strong>
         – Seizures have been reported infrequently during initial chelation therapy or later in the course of disease [
         <a href="#rid35">
          35,36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dysautonomia
         </strong>
         – Dysautonomia (eg, abnormal cardiac responses to the Valsalva maneuver) has been reported in Wilson disease usually in combination with other neurologic symptoms [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other neurologic manifestations
         </strong>
         – Other reported manifestations include hyperreflexia/hyperkinetic movements, myoclonus, and drooling.
        </p>
        <p>
        </p>
        <p>
         Magnetic resonance imaging (MRI) of the brain may reveal structural abnormalities in the basal ganglia or striatal and thalamic atrophy [
         <a href="#rid38">
          38-40
         </a>
         ]. Common findings in the basal ganglia include increased density on T2-weighted MRI images. Other findings include T2 hyperintensities in the tectal-plate and central pons. Simultaneous involvement of the basal ganglia, thalamus, and brainstem is highly suggestive of Wilson disease. Midbrain involvement sometimes appears as the "face of the giant panda," with the pontine changes resembling the face of a cub. This constitutes the characteristic "double panda sign."
        </p>
        <p class="headingAnchor" id="H69500449">
         <span class="h3">
          Psychiatric symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Psychiatric symptoms are common and may occur alone or in combination with liver and/or neurologic manifestations. Symptoms are generally nonspecific and include mood disorders (depression or bipolar spectrum), psychosis, sleep disturbance, and cognitive changes [
         <a href="#rid17">
          17
         </a>
         ]. Less common psychiatric manifestations of Wilson disease are personality changes (which may be subtle), irritability, impulsivity, labile mood, and declining academic/work performance [
         <a href="#rid41">
          41-43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2072539399">
         <span class="h3">
          Ocular involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Kayser-Fleischer (KF) rings are golden-brownish rings that result from fine, pigmented, granular deposits of copper in the periphery of the cornea  (
         <a class="graphic graphic_picture graphicRef65925" href="/z/d/graphic/65925.html" rel="external">
          picture 2
         </a>
         ). KF rings are a characteristic feature of Wilson disease found in nearly all patients with neurologic involvement and in approximately 50 percent of patients with liver disease. KF rings are usually detected by slit-lamp examination or by anterior segment optical tomography [
         <a href="#rid44">
          44-47
         </a>
         ]. Optical tomography can also quantify the ring size [
         <a href="#rid48">
          48
         </a>
         ]. KF rings dissipate over time with chelation or zinc therapy or following liver transplantation. (See
         <a class="medical medical_review" href="/z/d/html/259.html" rel="external">
          "Slit lamp examination"
         </a>
         .)
        </p>
        <p>
         Sunflower cataracts are another ocular manifestation of Wilson disease and occur when copper deposits accumulate in the lens. These are generally detected by slit-lamp examination [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H69500456">
         <span class="h3">
          Other organs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Less common manifestations of Wilson disease related to copper deposition in other organs are [
         <a href="#rid44">
          44
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kidney – Kidney abnormalities include Fanconi syndrome, in which proximal tubular dysfunction leads to glucosuria, aminoaciduria, hypouricemia (related to an increase in uric acid secretion), proximal renal tubular acidosis, and distal renal tubular acidosis that results in nephrolithiasis. (See
         <a class="medical medical_review" href="/z/d/html/2328.html" rel="external">
          "Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis", section on 'Proximal (type 2) RTA'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2369.html" rel="external">
          "Nephrolithiasis in renal tubular acidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rheumatologic – Rheumatologic manifestations include myopathy of the proximal limb muscles and arthropathy with premature arthritis and occasionally chondrocalcinosis, most commonly in the knee.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac – Cardiomyopathy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endocrine organs – Hypoparathyroidism; gigantism; female infertility and/or recurrent pregnancy loss; male sexual dysfunction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dermatologic – Blue lunulae (lunulae ceruleae), acanthosis nigricans, and pretibial hyperpigmentation.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1327623524">
         <span class="h2">
          Hemolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Non-immune (Coombs-negative) hemolytic anemia may rarely be the initial presentation of Wilson disease and is not uniformly associated with acute liver failure [
         <a href="#rid50">
          50,51
         </a>
         ]. In a series of 283 patients with Wilson disease, hemolytic anemia was the sole presenting feature in three patients (1 percent), but it was present in 19 of 77 patients (28 percent) who had jaundice at presentation [
         <a href="#rid50">
          50
         </a>
         ]. Hemolytic anemia may occur as a single acute episode, or it may be low-grade, episodic, or chronic.
        </p>
        <p>
         Patients reporting a history of jaundice prior to the diagnosis may have had previously unrecognized hemolysis [
         <a href="#rid52">
          52
         </a>
         ]. If acute hepatitis and hemolysis due to Wilson disease develop during pregnancy, it may be mistaken for HELLP syndrome. In patients with acute liver failure, hemoglobin &lt;10 g/dL has been associated with a 94 percent sensitivity but only 74 percent specificity for a diagnosis of Wilson disease [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5932.html" rel="external">
          "Overview of hemolytic anemias in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">
          "Diagnosis of hemolytic anemia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6778.html" rel="external">
          "HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H65234856">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H65234572">
         <span class="h2">
          When to suspect Wilson disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Wilson disease may be suspected in patients with any of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unexplained liver biochemical abnormalities (eg, elevated aminotransferases), especially if they are accompanied by neurologic or psychiatric symptoms. (See
         <a class="local">
          'Liver disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low ceruloplasmin (&lt;20 mg/dL [&lt;200 mg/L], with higher suspicion if ceruloplasmin is &lt;14 mg/dL [&lt;140 mg/L]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A first-degree relative with Wilson disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other clinical feature suggestive of copper overload:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chronic liver disease or cirrhosis of uncertain etiology (eg, patients with autoimmune hepatitis who do not respond to therapy, patients with liver steatosis in the absence of metabolic risk factors). (See
         <a class="medical medical_review" href="/z/d/html/3665.html" rel="external">
          "Overview of autoimmune hepatitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3625.html" rel="external">
          "Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acute liver failure in combination with other features of Wilson disease (eg, non-immune hemolytic anemia). (See
         <a class="local">
          'Acute liver injury/failure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Unexplained neurologic symptoms (eg, parkinsonian-like rest tremor, rigidity, gait abnormality, slurring of speech, facial grimacing [risus sardonicus]).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Unexplained psychiatric symptoms, ranging from changes in personality or work/school performance to depression or psychosis. (See
         <a class="local">
          'Neurologic involvement'
         </a>
         above and
         <a class="local">
          'Psychiatric symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3151387972">
         <span class="h2">
          Symptomatic patients
         </span>
        </p>
        <p class="headingAnchor" id="H65234579">
         <span class="h3">
          Initial testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         For symptomatic patients, we use a stepwise approach to establish the diagnosis of Wilson disease. Testing begins with an ocular examination for Kayser-Fleischer (KF) rings and laboratory studies. If initial testing is inconclusive, we obtain liver biopsy and/or genetic testing. (See
         <a class="local">
          'When to suspect Wilson disease'
         </a>
         above and
         <a class="local">
          'Subsequent testing'
         </a>
         below.)
        </p>
        <p>
         Initial testing includes  (
         <a class="graphic graphic_table graphicRef142021" href="/z/d/graphic/142021.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An ocular slit-lamp examination or anterior segment optical tomography
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         24-hour urinary copper excretion
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum ceruloplasmin
        </p>
        <p>
        </p>
        <p>
         We also measure serum aminotransferases, complete blood count, and serum copper concentration during the initial laboratory evaluation.
        </p>
        <p>
         We obtain the following in selected patients:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with acute liver injury/failure, we evaluate for non-immune hemolytic anemia  (
         <a class="graphic graphic_table graphicRef126234" href="/z/d/graphic/126234.html" rel="external">
          table 2
         </a>
         ). The diagnosis of hemolytic anemia is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">
          "Diagnosis of hemolytic anemia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with neurologic symptoms, we obtain brain imaging, usually with MRI without contrast enhancement.
        </p>
        <p>
        </p>
        <p>
         Liver biopsy is not always necessary because the diagnosis can be established in some patients with noninvasive testing and ocular examination. (See
         <a class="local">
          'Patients with KF rings'
         </a>
         below and
         <a class="local">
          'Patients without KF rings'
         </a>
         below.)
        </p>
        <p>
         We also use a standardized scoring system as part of the assessment  (
         <a class="graphic graphic_table graphicRef105282" href="/z/d/graphic/105282.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Diagnostic scoring system'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H65235537">
         <span class="h4">
          Patients with KF rings
         </span>
         <span class="headingEndMark">
          —
         </span>
         For symptomatic patients with KF rings, the diagnosis of Wilson disease is established if either of following criteria are met  (
         <a class="graphic graphic_algorithm graphicRef104976" href="/z/d/graphic/104976.html" rel="external">
          algorithm 1
         </a>
         ) (see
         <a class="local">
          'Manifestations of copper accumulation'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         24-hour urinary copper excretion &gt;40 mcg/24 hours (0.64 micromol/24 hours) in addition to ceruloplasmin &lt;20 mg/dL (200 mg/L), or
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         24-hour urinary copper excretion &gt;100 mcg/24 hours (1.6 micromol/24 hours), regardless of ceruloplasmin level
        </p>
        <p>
        </p>
        <p>
         For patients who do not meet either of these criteria, we obtain a liver biopsy to determine the hepatic copper concentration and/or molecular genetic testing for
         <em>
          ATP7B
         </em>
         mutations. For patients with discordant findings (eg, symptomatic patient with KF ring, elevated urinary copper excretion but normal ceruloplasmin), we typically obtain genetic testing also because normal ceruloplasmin is uncommon in patients with Wilson disease. (See
         <a class="local">
          'Subsequent testing'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1798646634">
         <span class="h4">
          Patients without KF rings
         </span>
         <span class="headingEndMark">
          —
         </span>
         For symptomatic patients without KF rings, the diagnosis of Wilson disease is established if the following criteria are met  (
         <a class="graphic graphic_algorithm graphicRef141163" href="/z/d/graphic/141163.html" rel="external">
          algorithm 2
         </a>
         ) (see
         <a class="local">
          'Manifestations of copper accumulation'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         24-hour urinary copper excretion &gt;100 mcg/24 hours (1.6 micromol/24 hours) in addition to ceruloplasmin &lt;10 mg/dL (&lt;100 mg/L)
        </p>
        <p>
        </p>
        <p>
         For patients with either ceruloplasmin &lt;10 mg/dL only or elevated 24-hour urinary copper excretion (ie, &gt;40 mcg/24 hours [0.64 micromol/24 hours]) only, we obtain a liver biopsy to determine the hepatic copper concentration and/or genetic testing for
         <em>
          ATP7B
         </em>
         mutations. (See
         <a class="local">
          'Subsequent testing'
         </a>
         below.)
        </p>
        <p>
         For symptomatic patients (eg, elevated aminotransferases, hepatomegaly) with ceruloplasmin ≥10 mg/dL and 24-hour urinary copper excretion ≤40 mcg/24 hours (0.64 micromol/24 hours), the diagnosis of Wilson disease is excluded.
        </p>
        <p class="headingAnchor" id="H65235551">
         <span class="h3">
          Subsequent testing
         </span>
        </p>
        <p class="headingAnchor" id="H1270275710">
         <span class="h4">
          Liver biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with inconclusive initial testing who undergo a liver biopsy, we determine hepatic copper concentration [
         <a href="#rid23">
          23,53
         </a>
         ] (see
         <a class="local">
          'Initial testing'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A diagnosis of Wilson disease is established if the hepatic copper concentration is &gt;250 mcg/g dry weight (4 micromol/g dry weight).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A diagnosis of Wilson disease is excluded if the hepatic copper concentration is &lt;50 mcg/g dry weight (0.8 micromol/g dry weight).
        </p>
        <p>
        </p>
        <p>
         If the hepatic copper concentration is between 50 and 250 mcg/g dry weight liver, we obtain molecular genetic testing for
         <em>
          ATP7B
         </em>
         mutations. In addition, we obtain genetic testing if we suspect sampling variation leading to a falsely normal hepatic copper concentration. (See
         <a class="local">
          'Genetic testing'
         </a>
         below.)
        </p>
        <p>
         Liver biopsies in patients suspected of having Wilson disease should include one needle core specimen for histology and one for copper quantitation that are both at least 1 cm in length. The specimen for copper quantitation should be placed in a dry, copper-free container [
         <a href="#rid27">
          27
         </a>
         ]. Specimen collection methods for copper quantitation, such as freezing or vacuum drying the specimen, prevent tissue destruction and provide accurate specimen weight. (See
         <a class="medical medical_review" href="/z/d/html/3587.html" rel="external">
          "Approach to liver biopsy"
         </a>
         .)
        </p>
        <p>
         In addition to being widely available, liver biopsy informs disease staging and excludes other causes of liver disease.
        </p>
        <p class="headingAnchor" id="H2980869832">
         <span class="h4">
          Genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         We use genetic testing when the diagnosis remains uncertain despite initial testing, when liver biopsy is not possible or inconclusive (ie, hepatic copper concentration between 50 and 250 mcg/g dry weight liver), and for evaluating siblings when the mutations in the proband are known. (See
         <a class="local">
          'Initial testing'
         </a>
         above.)
        </p>
        <p>
         We refer patients who undergo genetic testing to a genetic counselor. (See
         <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">
          "Genetic testing"
         </a>
         .)
        </p>
        <p>
         Biallelic, pathogenic (disease-causing) variants affecting both ATP7B alleles are required to develop Wilson disease. The genetics of Wilson disease and interpretation of genetic testing are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3626.html" rel="external">
          "Wilson disease: Epidemiology and pathogenesis", section on 'Genetic defect in Wilson disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/131793.html" rel="external">
          "Gene test interpretation:
          <i>
           ATP7B
          </i>
          (Wilson disease gene)"
         </a>
         .)
        </p>
        <p>
         A database of mutations in
         <em>
          ATP7B
         </em>
         (the gene mutated in Wilson disease) is available
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclingen.igib.res.in%2FWilsonGen%2F&amp;token=ZR7NcxeboUQthLDBd%2B6jTMAwhsetee8KsbiNOx7obET4nEWKLN7g2i3m%2BXFtYtXm&amp;TOPIC_ID=83837" target="_blank">
          online
         </a>
         [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H317179310">
         <span class="h3">
          Diagnostic scoring system
         </span>
         <span class="headingEndMark">
          —
         </span>
         A scoring system for assessing the certainty of the diagnosis was developed at an international meeting in Leipzig, Germany [
         <a href="#rid55">
          55
         </a>
         ]. The scoring system includes biochemical testing (eg, ceruloplasmin, urinary copper excretion), clinical manifestations (KF rings and neurologic symptoms), and molecular testing for
         <em>
          ATP7B
         </em>
         mutations  (
         <a class="graphic graphic_table graphicRef105282" href="/z/d/graphic/105282.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid27">
          27
         </a>
         ]. If the score is ≥4, Wilson disease is highly likely; if it is 3, the diagnosis is probable, but additional testing is needed (eg, obtaining a liver biopsy if not already done); if it is ≤2, Wilson disease is unlikely.
        </p>
        <p class="headingAnchor" id="H65234586">
         <span class="h2">
          Asymptomatic first-degree relatives
         </span>
         <span class="headingEndMark">
          —
         </span>
         All first-degree relatives of patients diagnosed with Wilson disease require evaluation, and we screen siblings with
         <em>
          ATP7B
         </em>
         genetic testing based on the proband  (
         <a class="graphic graphic_algorithm graphicRef133267" href="/z/d/graphic/133267.html" rel="external">
          algorithm 3
         </a>
         ). Because direct mutation analysis is available, targeted testing of siblings is specific and generally cost-effective. Interpretation of genetic testing for
         <em>
          ATP7B
         </em>
         is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/131793.html" rel="external">
          "Gene test interpretation:
          <i>
           ATP7B
          </i>
          (Wilson disease gene)"
         </a>
         .)
        </p>
        <p>
         If genetic testing is not available, we evaluate siblings with clinical and laboratory testing similar to the evaluation for patients with clinical features but no family history of Wilson disease. (See
         <a class="local">
          'Initial testing'
         </a>
         above.)
        </p>
        <p>
         For asymptomatic siblings diagnosed by genetic screening, we also assess for copper overload by measuring 24-hour urinary copper excretion or hepatic copper concentration because individuals with two disease‐causing mutations do not always have abnormal copper metabolism.
        </p>
        <p class="headingAnchor" id="H2630578918">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of Wilson disease includes conditions associated with chronic liver inflammation or acute liver injury, in addition to conditions with similar neuropsychiatric features:
        </p>
        <p class="headingAnchor" id="H2297567257">
         <span class="h2">
          Other causes of liver disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evaluation for other causes of liver disease is informed by patient presentation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic hepatitis with or without cirrhosis – Similar to Wilson disease, individuals with other causes of chronic liver disease may have elevated aminotransferases but do not have low ceruloplasmin. Such disorders include viral hepatitis, alcohol use disorder, autoimmune hepatitis, drug-induced liver injury, hereditary hemochromatosis, and alpha-1 antitrypsin deficiency. In patients with Wilson disease, the serum aminotransferases are usually mildly to moderately elevated (ie, &lt;5 times the upper limit of normal), and the aspartate aminotransferase (AST) concentration is usually higher than the alanine aminotransferase (ALT) concentration. (See
         <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">
          "Approach to the patient with abnormal liver biochemical and function tests"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Similarly, in patients presenting with cirrhosis, we evaluate patients for other causes of chronic liver disease, such as viral hepatitis. (See
         <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">
          "Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute liver injury – The differential diagnosis of acute liver injury that progresses to liver failure is broad and includes toxins, viral hepatitis, ischemia, and autoimmune hepatitis. Among patients with acute liver failure due to Wilson disease, the serum aminotransferases are typically less than 2000 international units/L with an AST/ALT ratio of &gt;2 [
         <a href="#rid16">
          16
         </a>
         ]. In addition, the alkaline phosphatase level is typically normal or below the normal range, with an alkaline phosphatase (international unit/L) to total bilirubin (mg/dL) ratio of &lt;4. Finally, patients with acute liver failure due to Wilson disease typically develop a non-immune hemolytic anemia and may have a low uric acid level. (See
         <a class="medical medical_review" href="/z/d/html/3574.html" rel="external">
          "Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16142.html" rel="external">
          "Acute liver failure in children: Etiology and evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3595487119">
         <span class="h2">
          Other causes of neurologic symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         The neurologic manifestations of Wilson disease vary widely and can mimic other neurologic disorders, especially any type of movement disorder. The differential diagnosis includes essential tremor, young-onset Parkinson disease, and generalized dystonia. The presence of KF rings, seen in nearly all patients with neurologic Wilson disease, help differentiate Wilson disease from other disorders. In addition, patterns of injury on brain imaging (eg, MRI) may support the diagnosis of Wilson disease [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4895.html" rel="external">
          "Overview of tremor"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4886.html" rel="external">
          "Etiology, clinical features, and diagnostic evaluation of dystonia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6231.html" rel="external">
          "Bradykinetic movement disorders in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14122.html" rel="external">
          "Neuroacanthocytosis"
         </a>
         .)
        </p>
        <p>
         In addition, neurologic symptoms may be related to hepatic encephalopathy that occurs in patients with portosystemic shunting, decompensated cirrhosis, or acute liver failure. (See
         <a class="medical medical_review" href="/z/d/html/1237.html" rel="external">
          "Hepatic encephalopathy in adults: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4117148502">
         <span class="h2">
          Other causes of psychiatric symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis for the psychiatric manifestations of Wilson disease includes depression, bipolar disorder, schizophrenia, dementia, and substance use disorder. As with the neurologic manifestations, KF rings can help differentiate patients with Wilson disease from these other disorders. (See
         <a class="medical medical_review" href="/z/d/html/1721.html" rel="external">
          "Unipolar depression in adults: Assessment and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/678.html" rel="external">
          "Bipolar disorder in adults: Epidemiology and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6962.html" rel="external">
          "Schizophrenia in adults: Clinical features, assessment, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H69501333">
         <span class="h1">
          DISEASE COURSE
         </span>
        </p>
        <p class="headingAnchor" id="H3288980">
         <span class="h2">
          Progressive multisystem disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with disease limited to the liver and who respond to drug therapy are unlikely to develop neurologic symptoms [
         <a href="#rid57">
          57
         </a>
         ]. However, for patients with untreated Wilson disease, copper accumulation in the liver eventually leads to cirrhosis and complications of portal hypertension (eg, ascites, variceal bleeding).
        </p>
        <p>
         Among untreated patients with neurologic involvement, the neurologic symptoms may progress until the patient becomes severely dystonic, akinetic, and mute. Progression is usually gradual, but sudden deterioration may also occur. Mortality is usually related to liver disease (decompensated cirrhosis or acute liver failure), although some patients succumb to complications from progressive neurologic disease. (See
         <a class="local">
          'Survival'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3288987">
         <span class="h2">
          Survival
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who achieve copper detoxification before developing cirrhosis and who maintain normal copper balance, overall survival is not significantly different compared with the general population [
         <a href="#rid3">
          3,58-61
         </a>
         ].
        </p>
        <p>
         Although life expectancy for untreated patients with Wilson disease is uncertain, lack of pharmacologic therapy and/or liver transplantation typically results in progressive symptoms, liver failure with complications of portal hypertension, and death. In addition, the estimated mortality rate for patients with Wilson disease complicated by acute liver failure who do not receive liver transplantation is 95 percent, with death usually occurring in days to weeks [
         <a href="#rid62">
          62
         </a>
         ]. However, liver transplantation cures Wilson disease, and long-term outcomes following liver transplantation are generally excellent [
         <a href="#rid63">
          63
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3591.html" rel="external">
          "Wilson disease: Management", section on 'Nonresponders'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H69500463">
         <span class="h2">
          Risk of liver cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with cirrhosis related to Wilson disease, we typically screen for hepatocellular carcinoma (HCC) using transabdominal ultrasound, and this approach is consistent with society guidelines [
         <a href="#rid17">
          17,64-66
         </a>
         ]. Indications for surveillance, routine surveillance intervals, and management of imaging results are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3583.html" rel="external">
          "Surveillance for hepatocellular carcinoma in adults", section on 'Patients with cirrhosis'
         </a>
         .)
        </p>
        <p>
         Whether the risk of HCC in patients with Wilson disease and cirrhosis meets the threshold for cost effective HCC surveillance is uncertain because data are limited [
         <a href="#rid64">
          64-67
         </a>
         ]. Cost-effectiveness models suggested that in patients with cirrhosis, surveillance becomes cost-effective once the annual incidence of HCC exceeds 1.5 percent [
         <a href="#rid68">
          68
         </a>
         ]. In a study including 130 patients with Wilson disease and cirrhosis who were followed for a mean of 15 years, two patients developed HCC (1.5 percent) [
         <a href="#rid65">
          65
         </a>
         ]. The estimated annual HCC risk in patients with cirrhosis was 0.14 percent. In a single center study including 71 patients with Wilson disease who were followed for a mean of 92 months, five patients (7 percent) developed HCC [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1172829160">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116713.html" rel="external">
          "Society guideline links: Inherited liver disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H69501155">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Background
         </strong>
         – Wilson disease (also referred to as hepatolenticular degeneration) is a genetic disorder of copper metabolism that leads to impaired function of the intracellular copper transporter ATP7B. Reduced biliary excretion of copper results in its accumulation in the liver and other tissues (eg, brain, cornea). Most patients have liver involvement that may range from asymptomatic abnormalities in liver biochemistries (eg, elevated serum aminotransferases) to cirrhosis to acute liver injury/failure. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Most patients with Wilson disease are diagnosed between the ages of 3 and 55 years, although it has been diagnosed in younger patients and in patients in their eighth decade of life. (See
         <a class="local">
          'Age at symptom onset'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The spectrum of presentation ranges from asymptomatic patients to those with symptoms related to liver, neurologic and/or psychiatric involvement:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Liver disease
         </strong>
         – At the time of diagnosis, most patients have some degree of liver disease that ranges from asymptomatic abnormalities in liver biochemistries to cirrhosis or acute liver injury. (See
         <a class="local">
          'Liver disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Neurologic symptoms
         </strong>
         – Common manifestations of neurologic involvement include dysarthria and movement disorders (eg, gait abnormalities, dystonia, tremor, parkinsonism). (See
         <a class="local">
          'Neurologic involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Psychiatric symptoms
         </strong>
         –
         <strong>
         </strong>
         Psychiatric symptoms are generally nonspecific and include mood disorders, psychosis, sleep disturbance, and cognitive changes. (See
         <a class="local">
          'Psychiatric symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other manifestations
         </strong>
         – Other clinical and laboratory manifestations include Kayser-Fleischer rings  (
         <a class="graphic graphic_picture graphicRef65925" href="/z/d/graphic/65925.html" rel="external">
          picture 2
         </a>
         ) and non-immune (Coombs-negative) hemolytic anemia. (See
         <a class="local">
          'Ocular involvement'
         </a>
         above and
         <a class="local">
          'Hemolysis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          When to suspect Wilson disease
         </strong>
         – Wilson disease may be suspected in patients with any of the following (see
         <a class="local">
          'When to suspect Wilson disease'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Unexplained liver biochemical abnormalities (eg, elevated aminotransferases), especially if they are accompanied by neurologic or psychiatric symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Low ceruloplasmin (&lt;20 mg/dL [&lt;200 mg/L] with higher suspicion if ceruloplasmin is &lt;14 mg/dL [&lt;140 mg/L]).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A first-degree relative with Wilson disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other feature suggestive of copper overload (eg, chronic liver disease of uncertain etiology, unexplained neurologic symptoms such as dysarthria, gait abnormality).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         –
         <strong>
         </strong>
         Initial diagnostic testing includes an ocular slit-lamp examination (or anterior segment optical tomography), 24-hour urinary copper excretion, and serum ceruloplasmin  (
         <a class="graphic graphic_table graphicRef142021" href="/z/d/graphic/142021.html" rel="external">
          table 1
         </a>
         ). Liver biopsy is not always necessary because the diagnosis can be established in some patients with noninvasive testing and ocular examination  (
         <a class="graphic graphic_algorithm graphicRef104976" href="/z/d/graphic/104976.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef141163" href="/z/d/graphic/141163.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients in whom the diagnosis remains suspected but not established based on initial testing, additional studies include liver biopsy to assess hepatic copper concentration and/or molecular genetic testing to evaluate for pathogenic (disease-causing) variants affecting both ATP7B alleles.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We also use a standardized scoring system as part of the assessment  (
         <a class="graphic graphic_table graphicRef105282" href="/z/d/graphic/105282.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease course
         </strong>
         – The prognosis for patients who achieve copper detoxification before developing cirrhosis and who maintain normal copper balance is excellent. (See
         <a class="medical medical_review" href="/z/d/html/3591.html" rel="external">
          "Wilson disease: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although life expectancy for untreated patients with Wilson disease is uncertain, lack of pharmacologic therapy and/or liver transplantation generally results in progressive symptoms, liver failure with complications of portal hypertension, and death. (See
         <a class="local">
          'Disease course'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lorincz MT. Neurologic Wilson's disease. Ann N Y Acad Sci 2010; 1184:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poujois A, Woimant F. Wilson's disease: A 2017 update. Clin Res Hepatol Gastroenterol 2018; 42:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taly AB, Meenakshi-Sundaram S, Sinha S, et al. Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore) 2007; 86:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Machado A, Chien HF, Deguti MM, et al. Neurological manifestations in Wilson's disease: Report of 119 cases. Mov Disord 2006; 21:2192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soltanzadeh A, Soltanzadeh P, Nafissi S, et al. Wilson's disease: a great masquerader. Eur Neurol 2007; 57:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noureen N, Rana MT. Neurological Wilson disease in children: a three years experience from Multan. J Pak Med Assoc 2011; 61:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asadi Pooya AA, Eslami NS, Haghighat M. Wilson disease in southern Iran. Turk J Gastroenterol 2005; 16:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moores A, Fox S, Lang A, Hirschfield GM. Wilson disease: Canadian perspectives on presentation and outcomes from an adult ambulatory setting. Can J Gastroenterol 2012; 26:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin LJ, Wang DX, Ding NN, et al. Comprehensive analysis on clinical features of Wilson's disease: an experience over 28 years with 133 cases. Neurol Res 2014; 36:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiernicka A, Dądalski M, Jańczyk W, et al. Early Onset of Wilson Disease: Diagnostic Challenges. J Pediatr Gastroenterol Nutr 2017; 65:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ala A, Borjigin J, Rochwarger A, Schilsky M. Wilson disease in septuagenarian siblings: Raising the bar for diagnosis. Hepatology 2005; 41:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manolaki N, Nikolopoulou G, Daikos GL, et al. Wilson disease in children: analysis of 57 cases. J Pediatr Gastroenterol Nutr 2009; 48:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ala A, Schilsky ML. Wilson disease: pathophysiology, diagnosis, treatment, and screening. Clin Liver Dis 2004; 8:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferenci P. Pathophysiology and clinical features of Wilson disease. Metab Brain Dis 2004; 19:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huster D. Wilson disease. Best Pract Res Clin Gastroenterol 2010; 24:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korman JD, Volenberg I, Balko J, et al. Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology 2008; 48:1167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schilsky ML, Roberts EA, Bronstein JM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases. Hepatology 2023; 77:1428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferlan-Marolt V, Stepec S. Fulminant Wilsonian hepatitis unmasked by disease progression: report of a case and review of the literature. Dig Dis Sci 1999; 44:1054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steindl P, Ferenci P, Dienes HP, et al. Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 1997; 113:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walia BN, Singh S, Marwaha RK, et al. Fulminant hepatic failure and acute intravascular haemolysis as presenting manifestations of Wilson's disease in young children. J Gastroenterol Hepatol 1992; 7:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferenci P, Stremmel W, Członkowska A, et al. Age and Sex but Not ATP7B Genotype Effectively Influence the Clinical Phenotype of Wilson Disease. Hepatology 2019; 69:1464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfeiffenberger J, Gotthardt DN, Herrmann T, et al. Iron metabolism and the role of HFE gene polymorphisms in Wilson disease. Liver Int 2012; 32:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferenci P, Steindl-Munda P, Vogel W, et al. Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease. Clin Gastroenterol Hepatol 2005; 3:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. Gut 2007; 56:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schilsky ML, Scheinberg IH, Sternlieb I. Liver transplantation for Wilson's disease: indications and outcome. Hepatology 1994; 19:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schilsky ML, Scheinberg IH, Sternlieb I. Prognosis of Wilsonian chronic active hepatitis. Gastroenterology 1991; 100:762.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol 2012; 56:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferenci P. Phenotype-genotype correlations in patients with Wilson's disease. Ann N Y Acad Sci 2014; 1315:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jung KH, Ahn TB, Jeon BS. Wilson disease with an initial manifestation of polyneuropathy. Arch Neurol 2005; 62:1628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Litwin T, Dzieżyc K, Karliński M, et al. Early neurological worsening in patients with Wilson's disease. J Neurol Sci 2015; 355:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mai N, Bolsinger P, Avarello M, et al. Control of isometric finger force in patients with cerebellar disease. Brain 1988; 111 ( Pt 5):973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massaquoi S, Hallett M. Kinematics of initiating a two-joint arm movement in patients with cerebellar ataxia. Can J Neurol Sci 1996; 23:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cardoso F, Seppi K, Mair KJ, et al. Seminar on choreas. Lancet Neurol 2006; 5:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walshe JM, Yealland M. Wilson's disease: the problem of delayed diagnosis. J Neurol Neurosurg Psychiatry 1992; 55:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dening TR, Berrios GE, Walshe JM. Wilson's disease and epilepsy. Brain 1988; 111 ( Pt 5):1139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Członkowska A, Litwin T, Chabik G. Wilson disease: neurologic features. Handb Clin Neurol 2017; 142:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhattacharya K, Velickovic M, Schilsky M, Kaufmann H. Autonomic cardiovascular reflexes in Wilson's disease. Clin Auton Res 2002; 12:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prashanth LK, Sinha S, Taly AB, Vasudev MK. Do MRI features distinguish Wilson's disease from other early onset extrapyramidal disorders? An analysis of 100 cases. Mov Disord 2010; 25:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tinaz S, Arora J, Nalamada K, et al. Structural and functional brain changes in hepatic and neurological Wilson disease. Brain Imaging Behav 2021; 15:2269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smolinski L, Ziemssen T, Akgun K, et al. Brain Atrophy Is Substantially Accelerated in Neurological Wilson's Disease: A Longitudinal Study. Mov Disord 2022; 37:2446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shanmugiah A, Sinha S, Taly AB, et al. Psychiatric manifestations in Wilson's disease: a cross-sectional analysis. J Neuropsychiatry Clin Neurosci 2008; 20:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svetel M, Potrebić A, Pekmezović T, et al. Neuropsychiatric aspects of treated Wilson's disease. Parkinsonism Relat Disord 2009; 15:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimbrean PC, Schilsky ML. Psychiatric aspects of Wilson disease: a review. Gen Hosp Psychiatry 2014; 36:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Członkowska A, Litwin T, Dusek P, et al. Wilson disease. Nat Rev Dis Primers 2018; 4:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broniek-Kowalik K, Dzieżyc K, Litwin T, et al. Anterior segment optical coherence tomography (AS-OCT) as a new method of detecting copper deposits forming the Kayser-Fleischer ring in patients with Wilson disease. Acta Ophthalmol 2019; 97:e757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Örmeci AÇ, Bayraktar Ş, Işık AO, et al. Is anterior segment OCT superior to slit-lamp biomicroscopic examination for Kayser Flesicher ring in Wilson's disease? Eur Rev Med Pharmacol Sci 2022; 26:5178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sridhar MS. Advantages of Anterior Segment Optical Coherence Tomography Evaluation of the Kayser-Fleischer Ring in Wilson Disease. Cornea 2017; 36:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sridhar MS, Pineda R. Anterior segment optical coherence tomography to look for Kayser-Fleischer rings. Pract Neurol 2017; 17:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goyal V, Tripathi M. Sunflower cataract in Wilson's disease. J Neurol Neurosurg Psychiatry 2000; 69:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saito T. Presenting symptoms and natural history of Wilson disease. Eur J Pediatr 1987; 146:261.
          </a>
         </li>
         <li class="breakAll">
          Walshe JM. The liver in Wilson's disease. In: Diseases of the liver, 6th ed, SchiffL, Schiff ER (Eds), Lippincott, Philadelphia 1987. p.1037-1050.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Czlonkowska A. A study of haemolysis in Wilson's disease. J Neurol Sci 1972; 16:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang X, Tang XP, Zhang YH, et al. Prospective evaluation of the diagnostic accuracy of hepatic copper content, as determined using the entire core of a liver biopsy sample. Hepatology 2015; 62:1731.
          </a>
         </li>
         <li class="breakAll">
          http://clingen.igib.res.in/WilsonGen/ (Accessed on April 17, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int 2003; 23:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dusek P, Smolinski L, Redzia-Ogrodnik B, et al. Semiquantitative Scale for Assessing Brain MRI Abnormalities in Wilson Disease: A Validation Study. Mov Disord 2020; 35:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubbioso R, Ranucci G, Esposito M, et al. Subclinical neurological involvement does not develop if Wilson's disease is treated early. Parkinsonism Relat Disord 2016; 24:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruha R, Marecek Z, Pospisilova L, et al. Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation. Liver Int 2011; 31:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheung KS, Seto WK, Fung J, et al. Epidemiology and natural history of Wilson's disease in the Chinese: A territory-based study in Hong Kong between 2000 and 2016. World J Gastroenterol 2017; 23:7716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beinhardt S, Leiss W, Stättermayer AF, et al. Long-term outcomes of patients with Wilson disease in a large Austrian cohort. Clin Gastroenterol Hepatol 2014; 12:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bem RS, Muzzillo DA, Deguti MM, et al. Wilson's disease in southern Brazil: a 40-year follow-up study. Clinics (Sao Paulo) 2011; 66:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gollan JL, Gollan TJ. Wilson disease in 1998: genetic, diagnostic and therapeutic aspects. J Hepatol 1998; 28 Suppl 1:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrarese A, Morelli MC, Carrai P, et al. Outcomes of Liver Transplant for Adults With Wilson's Disease. Liver Transpl 2020; 26:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfeiffenberger J, Mogler C, Gotthardt DN, et al. Hepatobiliary malignancies in Wilson disease. Liver Int 2015; 35:1615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Meer S, de Man RA, van den Berg AP, et al. No increased risk of hepatocellular carcinoma in cirrhosis due to Wilson disease during long-term follow-up. J Gastroenterol Hepatol 2015; 30:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walshe JM, Waldenström E, Sams V, et al. Abdominal malignancies in patients with Wilson's disease. QJM 2003; 96:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al Fadda M, Al Quaiz M, Al Ashgar H, et al. Wilson disease in 71 patients followed for over two decades in a tertiary center in Saudi Arabia: a retrospective review. Ann Saudi Med 2012; 32:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391:1301.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 83837 Version 33.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20146697" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Neurologic Wilson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29625923" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Wilson's disease: A 2017 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17435591" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Wilson disease: description of 282 patients evaluated over 3 decades.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17078070" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Neurological manifestations in Wilson's disease: Report of 119 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17179709" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Wilson's disease: a great masquerader.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22355993" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Neurological Wilson disease in children: a three years experience from Multan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16252195" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Wilson disease in southern Iran.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22720274" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Wilson disease: Canadian perspectives on presentation and outcomes from an adult ambulatory setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24107488" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Comprehensive analysis on clinical features of Wilson's disease: an experience over 28 years with 133 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28753182" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Early Onset of Wilson Disease: Diagnostic Challenges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15723329" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Wilson disease in septuagenarian siblings: Raising the bar for diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19172127" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Wilson disease in children: analysis of 57 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15464656" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Wilson disease: pathophysiology, diagnosis, treatment, and screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15554419" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pathophysiology and clinical features of Wilson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20955957" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Wilson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18798336" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36152019" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10235618" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Fulminant Wilsonian hepatitis unmasked by disease progression: report of a case and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9207280" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Wilson's disease in patients presenting with liver disease: a diagnostic challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1515561" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Fulminant hepatic failure and acute intravascular haemolysis as presenting manifestations of Wilson's disease in young children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30232804" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Age and Sex but Not ATP7B Genotype Effectively Influence the Clinical Phenotype of Wilson Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22098612" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Iron metabolism and the role of HFE gene polymorphisms in Wilson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16234011" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16709660" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8119682" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Liver transplantation for Wilson's disease: indications and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1993498" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Prognosis of Wilsonian chronic active hepatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22340672" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : EASL Clinical Practice Guidelines: Wilson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24517292" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Phenotype-genotype correlations in patients with Wilson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16216950" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Wilson disease with an initial manifestation of polyneuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26071888" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Early neurological worsening in patients with Wilson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3179693" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Control of isometric finger force in patients with cerebellar disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8673959" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Kinematics of initiating a two-joint arm movement in patients with cerebellar ataxia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16781989" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Seminar on choreas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1527540" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Wilson's disease: the problem of delayed diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3052696" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Wilson's disease and epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28433096" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Wilson disease: neurologic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12269552" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Autonomic cardiovascular reflexes in Wilson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20437536" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Do MRI features distinguish Wilson's disease from other early onset extrapyramidal disorders? An analysis of 100 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33244627" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Structural and functional brain changes in hepatic and neurological Wilson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36165286" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Brain Atrophy Is Substantially Accelerated in Neurological Wilson's Disease: A Longitudinal Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18305288" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Psychiatric manifestations in Wilson's disease: a cross-sectional analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19559640" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Neuropsychiatric aspects of treated Wilson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24120023" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Psychiatric aspects of Wilson disease: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30190489" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Wilson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30635971" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Anterior segment optical coherence tomography (AS-OCT) as a new method of detecting copper deposits forming the Kayser-Fleischer ring in patients with Wilson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35916815" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Is anterior segment OCT superior to slit-lamp biomicroscopic examination for Kayser Flesicher ring in Wilson's disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28060027" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Advantages of Anterior Segment Optical Coherence Tomography Evaluation of the Kayser-Fleischer Ring in Wilson Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28270445" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Anterior segment optical coherence tomography to look for Kayser-Fleischer rings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10864623" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Sunflower cataract in Wilson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3595645" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Presenting symptoms and natural history of Wilson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3595645" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Presenting symptoms and natural history of Wilson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5038887" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : A study of haemolysis in Wilson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26095812" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Prospective evaluation of the diagnostic accuracy of hepatic copper content, as determined using the entire core of a liver biopsy sample.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26095812" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Prospective evaluation of the diagnostic accuracy of hepatic copper content, as determined using the entire core of a liver biopsy sample.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12955875" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Diagnosis and phenotypic classification of Wilson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32181965" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Semiquantitative Scale for Assessing Brain MRI Abnormalities in Wilson Disease: A Validation Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26851839" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Subclinical neurological involvement does not develop if Wilson's disease is treated early.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20958917" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29209112" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Epidemiology and natural history of Wilson's disease in the Chinese: A territory-based study in Hong Kong between 2000 and 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24076416" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Long-term outcomes of patients with Wilson disease in a large Austrian cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21552664" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Wilson's disease in southern Brazil: a 40-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9575447" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Wilson disease in 1998: genetic, diagnostic and therapeutic aspects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31901209" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Outcomes of Liver Transplant for Adults With Wilson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25369181" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Hepatobiliary malignancies in Wilson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25160780" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : No increased risk of hepatocellular carcinoma in cirrhosis due to Wilson disease during long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12925721" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Abdominal malignancies in patients with Wilson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23396027" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Wilson disease in 71 patients followed for over two decades in a tertiary center in Saudi Arabia: a retrospective review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29307467" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Hepatocellular carcinoma.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
